Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications
dc.contributor.author | Herman, W. H. | en_US |
dc.contributor.author | Pop‐busui, R. | en_US |
dc.contributor.author | Braffett, B. H. | en_US |
dc.contributor.author | Martin, C. L. | en_US |
dc.contributor.author | Cleary, P. A. | en_US |
dc.contributor.author | Albers, J. W. | en_US |
dc.contributor.author | Feldman, E. L. | en_US |
dc.date.accessioned | 2012-07-12T17:26:44Z | |
dc.date.available | 2013-09-03T15:38:26Z | en_US |
dc.date.issued | 2012-07 | en_US |
dc.identifier.citation | Herman, W. H.; Pop‐busui, R. ; Braffett, B. H.; Martin, C. L.; Cleary, P. A.; Albers, J. W.; Feldman, E. L. (2012). "Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Typeâ 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications." Diabetic Medicine 29(7). <http://hdl.handle.net/2027.42/92152> | en_US |
dc.identifier.issn | 0742-3071 | en_US |
dc.identifier.issn | 1464-5491 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/92152 | |
dc.description.abstract | Aims The Michigan Neuropathy Screening Instrument (MNSI) is used to assess distal symmetrical peripheral neuropathy in diabetes. It includes two separate assessments: a 15‐item self‐administered questionnaire and a lower extremity examination that includes inspection and assessment of vibratory sensation and ankle reflexes. The purpose of this study was to evaluate the performance of the MNSI in detecting distal symmetrical peripheral neuropathy in patients with Type 1 diabetes and to develop new scoring algorithms. Methods The MNSI was performed by trained personnel at each of the 28 Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications clinical sites. Neurologic examinations and nerve conduction studies were performed during the same year. Confirmed clinical neuropathy was defined by symptoms and signs of distal symmetrical peripheral neuropathy based on the examination of a neurologist and abnormal nerve conduction findings in ≥ 2 anatomically distinct nerves among the sural, peroneal and median nerves. Results We studied 1184 subjects with Type 1 diabetes. Mean age was 47 years and duration of diabetes was 26 years. Thirty per cent of participants had confirmed clinical neuropathy, 18% had ≥ 4 and 5% had ≥ 7 abnormal responses on the MNSI questionnaire, and 33% had abnormal scores (≥ 2.5) on the MNSI examination. New scoring algorithms were developed and cut points defined to improve the performance of the MNSI questionnaire, examination and the combination of the two. Conclusions Altering the cut point to define an abnormal test from ≥ 7 abnormal to ≥ 4 abnormal items improves the performance of the MNSI questionnaire. The MNSI is a simple, non‐invasive and valid measure of distal symmetrical peripheral neuropathy in Type 1 diabetes. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.subject.other | Measurement | en_US |
dc.subject.other | Peripheral Neuropathy | en_US |
dc.title | Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | The George Washington University, The Biostatistics Center, Rockville, MD, USA | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/92152/1/j.1464-5491.2012.03644.x.pdf | |
dc.identifier.doi | 10.1111/j.1464-5491.2012.03644.x | en_US |
dc.identifier.source | Diabetic Medicine | en_US |
dc.identifier.citedreference | Madalla GS. Limited‐Dependent and Qualitative Variables in Econometrics. Cambridge: Cambridge University Press, 1983. | en_US |
dc.identifier.citedreference | Zweig M, Campbell G. Receiver‐operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561 – 577. | en_US |
dc.identifier.citedreference | Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P et al. on the behalf of the Toronto Diabetic Neuropathy Expert Group Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285 – 2293. | en_US |
dc.identifier.citedreference | Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EV, Freeman R et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956 – 962. | en_US |
dc.identifier.citedreference | SAS Institute Inc. Logistic Regression Examples Using the SAS System. 1st edn, version 6. Cary, NC: SAS Institute Inc., 1995. | en_US |
dc.identifier.citedreference | Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two‐step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281 – 1289. | en_US |
dc.identifier.citedreference | The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. N Engl J Med 1993; 329: 977 – 986. | en_US |
dc.identifier.citedreference | The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561 – 568. | en_US |
dc.identifier.citedreference | The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38: 869 – 880. | en_US |
dc.identifier.citedreference | Albers JW, Herman WH, Pop‐Busui R, Feldman EL, Martin CL, Cleary PA et al. for the DCCT Research Group Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Diabetes Care 2010; 33: 1090 – 1096. | en_US |
dc.identifier.citedreference | Cox DR. The Analysis of Binary Data. 2nd edn. London: Chapman and Hall, 1970. | en_US |
dc.identifier.citedreference | Pop‐Busui R, Lu J, Lopes N, Jones TL; BARI 2D Investigators. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst 2009; 14: 1 – 13. | en_US |
dc.identifier.citedreference | Pop‐Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ et al.; Action to Control Cardiovascular Risk in Diabetes Study Group Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33: 1688 – 1690. | en_US |
dc.identifier.citedreference | Dyck PJ. Severity and staging of diabetic polyneuropathy. In: Gries FA, Cameron NE, Low PA, Ziegler D, eds. Textbook of Diabetic Neuropathy. New York, NY: Thieme New York, 2003: 170 – 174. | en_US |
dc.identifier.citedreference | Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997; 49: 229 – 239. | en_US |
dc.identifier.citedreference | England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence‐based review): Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009; 72: 177 – 184. | en_US |
dc.identifier.citedreference | England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT et al. Distal symmetric polyneuropathy: a definition for clinical research. Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64: 199 – 207. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.